Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Shveta Gupta, MBBS, Ayesha Zia, MD, Ravindra Sarode, MD

Blood (2019) 134 (Supplement_1): 4976.

https://doi.org/10.1182/blood-2019-129118

Published: 2019

Journal Articles

An Institutional Survey of Warfarin Reversal in the Setting of Life-Threatening Bleeds

Ian Garrahy, DO, Tushar Pawar, MD MPH, Anthony Donato, MD, Amber Stevenson, CMA, Daniel Forman, DO

Blood (2019) 134 (Supplement_1): 4981.

https://doi.org/10.1182/blood-2019-129065

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Lorraine Cafuir, MD, En Cheng, Christine L Kempton, MD MSc

Blood (2018) 132 (Supplement 1): 826.

https://doi.org/10.1182/blood-2018-99-110685

Published: 2018

Journal Articles

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2018-99-114426

Published: 2018

Journal Articles

Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System

Emma P. Deloughery, BS, Joseph J. Shatzel, MD

Blood (2018) 132 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2018-99-109822

Published: 2018

Journal Articles

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Meagan Scott, PharmD, Maho Hibino, PharmD, Marie Cavalier, PharmD, Bayard L. Powell, MD, Dianna S. Howard, MD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Susan Lyerly, P.A.-C., Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 2091.

https://doi.org/10.1182/blood.V130.Suppl_1.2091.2091

Published: 2017

Journal Articles

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Nasir Sadeghi, Zafar Siddiqui, Omer Iqbal, Schuharazad Abro, Debra Hoppensteadt, PhD, Michael Mosier, Jeanine Walenga, Jawed Fareed, PhD, Ahmed Kouta

Blood (2017) 130 (Supplement 1): 4868.

https://doi.org/10.1182/blood.V130.Suppl_1.4868.4868

Published: 2017

Journal Articles

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Mark Crowther, MD, Genmin Lu, PhD, Janet M. Leeds, PhD, Joyce Lin, BS, Pamela B. Conley, PhD, Alexander Gold, MD, Stuart J. Connolly, MD, John T. Curnutte, MD PhD

Blood (2016) 128 (22): 143.

https://doi.org/10.1182/blood.V128.22.143.143

Published: 2016

Journal Articles

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Manuela Albisetti, MD, Arno Schlosser, MSc, Martina Brueckmann, MD, Savion Gropper, MD, Stephan Glund, PhD, Igor Tartakovsky, MD, Leonardo R. Brandão, MD MSc, Paul A Reilly, PhD

Blood (2016) 128 (22): 5010.

https://doi.org/10.1182/blood.V128.22.5010.5010

Published: 2016

Journal Articles

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

Roberto Crea, DVM, MSc, Aaron Novack, Armin J Reininger, Justine Kennedy, Sandra Raff, Alessandro Gringeri, MD MSc, Naghmana Bajwa

Blood (2016) 128 (22): 5031.

https://doi.org/10.1182/blood.V128.22.5031.5031

Published: 2016

Journal Articles

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Leeds Janet, PhD, Genmin Lu, PhD, John T. Curnutte, MDPhD, Pamela B. Conley, PhD, Jaap W. Mandema, PhD

Blood (2015) 126 (23): 1135.

https://doi.org/10.1182/blood.V126.23.1135.1135

Published: 2015

Journal Articles

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Markus Honickel, MD, Joanne van Ryn, PhD, Oliver Grottke, MDPhD

Blood (2015) 126 (23): 1128.

https://doi.org/10.1182/blood.V126.23.1128.1128

Published: 2015

Journal Articles

Reversal of Trauma-Induced Bleeding and Anticoagulation with a Dabigatran-Specific Antidote (idarucizumab) As Assessed By Shed and Washed Blood Tests in a Pig Model of Supratherapeutic Anticoagulation and Trauma

Oliver Grottke, MD PhD, Markus Honickel, MD, Johanna Schurer, Joanne van Ryn, PhD

Blood (2014) 124 (21): 4268.

https://doi.org/10.1182/blood.V124.21.4268.4268

Published: 2014

Journal Articles

Efficacy and safety of Prothrombin Complex Concentrates Weight-Based Dosing for Reversal of Warfarin Anticoagulation

Rosanne St. Bernard, MD MSc, Kathleen Eckert, Alejandro Lazo-Langner, MD MSc, Ian H. Chin-Yee, MD FRCPC, Amanda Devraj, MD, Cyrus C. Hsia, BSc, MD FRCPC

Blood (2014) 124 (21): 4301.

https://doi.org/10.1182/blood.V124.21.4301.4301

Published: 2014

Journal Articles

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

Joseph Shaw, B.Sc, Gregoire Le Gal, MDPhD, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, MD, Marc Carrier, MDMSc, Lana Castellucci, MDMSc

Blood (2014) 124 (21): 4259.

https://doi.org/10.1182/blood.V124.21.4259.4259

Published: 2014

Journal Articles

Zymogen-like FXa Variant As a Short-Acting Warfarin Reversal Agent: Pre-Clinical Evaluation and Mechanism of Action

Lindsey A. Greene, MD, Nabil K. Thalji, BS, Leslie J. Raffini, MD, Rodney M. Camire, PhD

Blood (2014) 124 (21): 4262.

https://doi.org/10.1182/blood.V124.21.4262.4262

Published: 2014

Journal Articles

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation

Eva Herzog, PhD, Franz Kaspereit, Wilfried Krege, Peter Niebl, Stefan Schulte, PhD, Gerhard Dickneite, Prof. PhD

Blood (2014) 124 (21): 1472.

https://doi.org/10.1182/blood.V124.21.1472.1472

Published: 2014

Journal Articles

Ex Vivo Prothrombin Complex Concentrates and a Specific Antidote Are Effective In Reversing Dabigatran-Induced Coagulopathy In Pigs

Joanne van Ryn, PhD, Henri M.H. Spronk, PhD, Rolf Rossaint, MD, Oliver Grottke, MD, PhD

Blood (2013) 122 (21): 2387.

https://doi.org/10.1182/blood.V122.21.2387.2387

Published: 2013

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Crowther Mark, MD, Mathur Vandana, MD, Kitt Michael, MD, Lu Genmin, PhD, Pamela B. Conley, Ph.D., Hollenbach Stanley, JD, Janice Castillo, Athiwat Hutchaleelaha, Ph.D., Mark Karbarz, Ph.D., Joyce P. Lin, Lee Barron, PhD, Sandra Russell, R.N, Gallia G. Levy, MD, PhD, Stuart Connolly, M.D., John T. Curnutte, MD, PhD

Blood (2013) 122 (21): 3636.

https://doi.org/10.1182/blood.V122.21.3636.3636

Published: 2013

NARROW

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

An Institutional Survey of Warfarin Reversal in the Setting of Life-Threatening Bleeds

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Mechanistic Differences of Prothrombin Complex Concentrate and Idarucizumab in a Trauma Model Under Dabigatran Anticoagulation

Reversal of Trauma-Induced Bleeding and Anticoagulation with a Dabigatran-Specific Antidote (idarucizumab) As Assessed By Shed and Washed Blood Tests in a Pig Model of Supratherapeutic Anticoagulation and Trauma

Efficacy and safety of Prothrombin Complex Concentrates Weight-Based Dosing for Reversal of Warfarin Anticoagulation

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

Zymogen-like FXa Variant As a Short-Acting Warfarin Reversal Agent: Pre-Clinical Evaluation and Mechanism of Action

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation

Ex Vivo Prothrombin Complex Concentrates and a Specific Antidote Are Effective In Reversing Dabigatran-Induced Coagulopathy In Pigs

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only